Laura M Tormoehlen1, Ashley D Blatsioris1, Elizabeth A S Moser1, Ravan J L Carter1, Alec Stevenson1, Susan Ofner1, Abigail L Hulin1, Darren P O'Neill1, Aaron A Cohen-Gadol1, Thomas J Leipzig1, Linda S Williams1, Jason Mackey2. 1. From the Departments of Neurology (L.M.T., A.D.B., A.S., A.L.H., L.S.W., J.M.), Emergency Medicine (L.M.T.), Biostatistics (E.A.S.M., S.O.), Radiology (D.P.O.), and Neurosurgery (A.A.C.-G., T.J.L.), Indiana University School of Medicine; Regenstrief Institute (R.J.L.C., L.S.W., J.M.); and Richard L. Roudebush VA Medical Center (L.S.W.), Indianapolis, IN. 2. From the Departments of Neurology (L.M.T., A.D.B., A.S., A.L.H., L.S.W., J.M.), Emergency Medicine (L.M.T.), Biostatistics (E.A.S.M., S.O.), Radiology (D.P.O.), and Neurosurgery (A.A.C.-G., T.J.L.), Indiana University School of Medicine; Regenstrief Institute (R.J.L.C., L.S.W., J.M.); and Richard L. Roudebush VA Medical Center (L.S.W.), Indianapolis, IN. jsmackey@iupui.edu.
Abstract
OBJECTIVE: To characterize the pattern of urine drug screening in a cohort of intracerebral hemorrhage (ICH) patients at our academic centers. METHODS: We identified cases of primary ICH occurring from 2009 to 2011 in our academic centers. Demographic data, imaging characteristics, processes of care, and short-term outcomes were ascertained. We performed logistic regression to identify predictors for screening and evaluated preguideline and postguideline reiteration screening patterns. RESULTS: We identified 610 patients with primary ICH in 2009-2011; 379 (62.1%) were initially evaluated at an outside hospital. Overall, 142/610 (23.3%) patients were screened, with 21 positive for cocaine and 3 for amphetamine. Of patients <55 years of age, only 65/140 (46.4%) were screened. Black patients <55 years of age were screened more than nonblack patients <55 years of age (38/61 [62.3%] vs 27/79 [34.2%]; p = 0.0009). In the best multivariable model, age group (p = 0.0001), black race (p = 0.4529), first Glasgow Coma Scale score (p = 0.0492), current smoking (p < 0.0001), and age group × black race (p = 0.0097) were associated with screening. Guideline reiteration in 2010 did not improve the proportion <55 years of age who were screened: 42/74 (56.8%) were screened before and 23/66 (34.9%) after (p = 0.01). CONCLUSIONS: We found disparities in drugs of abuse (DOA) screening and suboptimal guideline adherence. Systematic efforts to improve screening for DOA are warranted. Improved identification of sympathomimetic exposure may improve etiologic classification and influence decision-making and prognosis counseling.
OBJECTIVE: To characterize the pattern of urine drug screening in a cohort of intracerebral hemorrhage (ICH) patients at our academic centers. METHODS: We identified cases of primary ICH occurring from 2009 to 2011 in our academic centers. Demographic data, imaging characteristics, processes of care, and short-term outcomes were ascertained. We performed logistic regression to identify predictors for screening and evaluated preguideline and postguideline reiteration screening patterns. RESULTS: We identified 610 patients with primary ICH in 2009-2011; 379 (62.1%) were initially evaluated at an outside hospital. Overall, 142/610 (23.3%) patients were screened, with 21 positive for cocaine and 3 for amphetamine. Of patients <55 years of age, only 65/140 (46.4%) were screened. Black patients <55 years of age were screened more than nonblack patients <55 years of age (38/61 [62.3%] vs 27/79 [34.2%]; p = 0.0009). In the best multivariable model, age group (p = 0.0001), black race (p = 0.4529), first Glasgow Coma Scale score (p = 0.0492), current smoking (p < 0.0001), and age group × black race (p = 0.0097) were associated with screening. Guideline reiteration in 2010 did not improve the proportion <55 years of age who were screened: 42/74 (56.8%) were screened before and 23/66 (34.9%) after (p = 0.01). CONCLUSIONS: We found disparities in drugs of abuse (DOA) screening and suboptimal guideline adherence. Systematic efforts to improve screening for DOA are warranted. Improved identification of sympathomimetic exposure may improve etiologic classification and influence decision-making and prognosis counseling.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Felipe de los Ríos; Dawn O Kleindorfer; Jane Khoury; Joseph P Broderick; Charles J Moomaw; Opeolu Adeoye; Matthew L Flaherty; Pooja Khatri; Daniel Woo; Kathleen Alwell; Jane Eilerman; Simona Ferioli; Brett M Kissela Journal: Stroke Date: 2012-11-15 Impact factor: 7.914
Authors: Sheryl Martin-Schild; Karen C Albright; Hen Hallevi; Andrew D Barreto; Maria Philip; Vivek Misra; James C Grotta; Sean I Savitz Journal: Stroke Date: 2010-02-25 Impact factor: 7.914
Authors: Lewis B Morgenstern; J Claude Hemphill; Craig Anderson; Kyra Becker; Joseph P Broderick; E Sander Connolly; Steven M Greenberg; James N Huang; R Loch MacDonald; Steven R Messé; Pamela H Mitchell; Magdy Selim; Rafael J Tamargo Journal: Stroke Date: 2010-07-22 Impact factor: 7.914
Authors: Charlotte Jj van Asch; Merel Ja Luitse; Gabriël Je Rinkel; Ingeborg van der Tweel; Ale Algra; Catharina Jm Klijn Journal: Lancet Neurol Date: 2010-01-05 Impact factor: 44.182
Authors: Brian Silver; Daniel Miller; Michelle Jankowski; Nawaf Murshed; Patricia Garcia; Patricia Penstone; Melissa Straub; Sean P Logan; Anita Sinha; Daniel C Morris; Angelos Katramados; Andrew N Russman; Panayiotis D Mitsias; Lonni R Schultz Journal: Neurology Date: 2013-04-17 Impact factor: 9.910
Authors: Joseph Broderick; Sander Connolly; Edward Feldmann; Daniel Hanley; Carlos Kase; Derk Krieger; Marc Mayberg; Lewis Morgenstern; Christopher S Ogilvy; Paul Vespa; Mario Zuccarello Journal: Circulation Date: 2007-10-16 Impact factor: 29.690
Authors: Matthew H M Marx; Karen C Albright; Amir Shaban; Amelia K Boehme; T Mark Beasley; Sheryl Martin-Schild Journal: Int Neuropsychiatr Dis J Date: 2014-05